Giovanni Corso
@ieo.it
1. Breast Surgery, 2. Department of Oncology and Hemato-Oncology
1. European Institute of Oncology, 2. University of Milan, 3. European Cancer Prevention Organization (ECP)
Corso graduated MD cum laude at the University of Siena Italy in 2002. He specialized in general surgery in 2009, and received PhD in Medicine and Molecular Oncology at the University of Porto Corso has published about 160 international articles, 16 chapters and two books with Springer Science+Business Media.
EDUCATION
2012
PhD Gaduation in Medicine and Molecular Oncology with laude. University of Porto, Portugal.
2009
Specialization in General Surgery with laude. University of Siena, Italy.
2002
MD graduation with laude in Medicine and Surgery. University of Siena, Italy.
RESEARCH, TEACHING, or OTHER INTERESTS
Surgery, Genetics (clinical), Health Policy
Scopus Publications
Scholar Citations
Scholar h-index
Scholar i10-index
Scopus Publications
Francesca Magnoni, Giovanni Corso, Patrick Maisonneuve, Beatrice Bianchi, Giuseppe Accardo, Claudia Sangalli, Giulia Massari, Anna Rotili, Luca Nicosia, Filippo Pesapane,et al.
Elsevier BV
Francesca Magnoni, Corrado Tinterri, Giovanni Corso, Giuseppe Curigliano, Maria Cristina Leonardi, Antonio Toesca, Nicola Rocco, Francesca Catalano, Beatrice Bianchi, Federica Lauria,et al.
Ovid Technologies (Wolters Kluwer Health)
A breast unit is a multidisciplinary center specialized in the management of women with breast diseases, including breast cancer (BC). It represents a care path, passing from screening activities to diagnostic investigations, from surgery to the definition of the therapeutic strategy, from psychophysical rehabilitation to long-term checks (follow-up), and up to genetic counseling. Since 2006, following a resolution issued by the European Parliament to urge member states to activate multidisciplinary breast centers by 2016, work has been underway throughout Italy to improve the management of women with BC. In Italy, the State-Regions agreement was signed on 18 December 2014, sanctioning the establishment of breast units. These centers must adhere to specific quality criteria and requirements. In 2020, the experts of the EUSOMA group (European Society of Breast Cancer Specialists), in their latest document published, expanded the requirements of the breast units. Furthermore, Senonetwork was founded in 2012 with the aim of allowing BC to be treated in breast units that comply with European requirements to ensure equal treatment opportunities for all Italian women. Indeed, the available data indicate that the BC patient has a greater chance of better treatment in the breast units with a multidisciplinary team, thus increasing the survival rate with a better quality of life, compared to those managed in nonspecialized structures. The present review is a perspective on the current Italian reality of breast units, updated with the available literature and the most recent epidemiological data from Senonetwork and AgeNaS.
Giovanni Corso, Jeremy L. Davis, and Vivian E. Strong
Wiley
AbstractPathogenic germline CDH1 mutation confers high risk for developing diffuse gastric and lobular breast cancers in asymptomatic carriers. In these individuals, the estimated gastric cancer risk at 80 years of age is up to 70% for males and 56% for females. Due to this high‐risk predisposition, prophylactic total gastrectomy is considered a unique life‐saving approach in germline CDH1 carriers, as endoscopy often fails to detect early stage diffuse gastric carcinoma. However, surgical indication is controversial in some clinical contexts, with possible contraindications. This review discusses points against and in favor of a more aggressive surgical approach for consideration during the decision‐making process.
Filippo Pesapane, Priyan Tantrige, Anna Rotili, Luca Nicosia, Silvia Penco, Anna Carla Bozzini, Sara Raimondi, Giovanni Corso, Roberto Grasso, Gabriella Pravettoni,et al.
MDPI AG
Access to medical imaging is pivotal in healthcare, playing a crucial role in the prevention, diagnosis, and management of diseases. However, disparities persist in this scenario, disproportionately affecting marginalized communities, racial and ethnic minorities, and individuals facing linguistic or cultural barriers. This paper critically assesses methods to mitigate these disparities, with a focus on breast cancer screening. We underscore scientific mobility as a vital tool for radiologists to advocate for healthcare policy changes: it not only enhances diversity and cultural competence within the radiology community but also fosters international cooperation and knowledge exchange among healthcare institutions. Efforts to ensure cultural competency among radiologists are discussed, including ongoing cultural education, sensitivity training, and workforce diversification. These initiatives are key to improving patient communication and reducing healthcare disparities. This paper also highlights the crucial role of policy changes and legislation in promoting equal access to essential screening services like mammography. We explore the challenges and potential of teleradiology in improving access to medical imaging in remote and underserved areas. In the era of artificial intelligence, this paper emphasizes the necessity of validating its models across a spectrum of populations to prevent bias and achieve equitable healthcare outcomes. Finally, the importance of international collaboration is illustrated, showcasing its role in sharing insights and strategies to overcome global access barriers in medical imaging. Overall, this paper offers a comprehensive overview of the challenges related to disparities in medical imaging access and proposes actionable strategies to address these challenges, aiming for equitable healthcare delivery.
Luca Nicosia, Anna Rotili, Filippo Pesapane, Anna Carla Bozzini, Ottavia Battaglia, Giuseppe Pellegrino, Nicola Fusco, Francesca Maria Porta, Samuele Frassoni, Vincenzo Bagnardi,et al.
Springer Science and Business Media LLC
F. Pesapane, Ottavia Battaglia, Giuseppe Pellegrino, Elisa Mangione, Salvatore Petitto, Eliza Del Fiol Manna, Laura Cazzaniga, Luca Nicosia, Matteo Lazzeroni, Giovanni Corso,et al.
Breast cancer risk models represent the likelihood of developing breast cancer based on risk factors. They enable personalized interventions to improve screening programs. Radiologists identify mammographic density as a significant risk factor and test new imaging techniques. Pathologists provide data for risk assessment. Clinicians conduct individual risk assessments and adopt prevention strategies for high-risk subjects. Tumor genetic testing guides personalized screening and treatment decisions. Artificial intelligence in mammography integrates imaging, clinical, genetic and pathological data to develop risk models. Emerging imaging technologies, genetic testing and molecular profiling improve risk model accuracy. The complexity of the disease, limited data availability and model inputs are discussed. A multidisciplinary approach is essential for earlier detection and improved outcomes.
Luciano Mariano, Luca Nicosia, Davide Pupo, Antonia Maria Olivieri, Sofia Scolari, Filippo Pesapane, Antuono Latronico, Anna Carla Bozzini, Nicola Fusco, Marta Cruz Blanco,et al.
MDPI AG
Mammary Paget disease (MPD) is a rare condition primarily affecting adult women, characterized by unilateral skin changes in the nipple–areolar complex (NAC) and frequently associated with underlying breast carcinoma. Histologically, MPD is identified by large intraepidermal epithelial cells (Paget cells) with distinct characteristics. Immunohistochemical profiles aid in distinguishing MPD from other skin conditions. Clinical evaluation and imaging techniques, including magnetic resonance imaging (MRI), are recommended if MPD is suspected, although definitive diagnosis always requires histological examination. This review delves into the historical context, epidemiology, pathogenesis, clinical manifestations, and diagnosis of MPD, emphasizing the need for early detection. The classification of MPD based on pathogenesis is explored, shedding light on its varied presentations. Treatment options, including mastectomy and breast-conserving surgery, are discussed with clear guidelines for different scenarios. Adjuvant therapies are considered, particularly in cases with underlying breast cancer. Prognostic factors are outlined, underlining the importance of early intervention. Looking to the future, emerging techniques, like liquid biopsy, new immunohistochemical and molecular markers, and artificial intelligence-based image analysis, hold the potential to transform MPD diagnosis and treatment. These innovations offer hope for early detection and improved patient care, though validation through large-scale clinical trials is needed.
Giovanni Corso, Giovanni Comelli, Paolo Veronesi, Beatrice Bianchi, Salvatore Petitto, Andrea Polizzi, Antonia Girardi, Antonio Cioffi, Carlo La Vecchia, Vincenzo Bagnardi,et al.
Springer Science and Business Media LLC
Giovanni Corso, Monica Marabelli, Mariarosaria Calvello, Sara Gandini, Matilde Risti, Irene Feroce, Sara Mannucci, Antonia Girardi, Alessandra Margherita De Scalzi, Francesca Magnoni,et al.
Springer Science and Business Media LLC
Filippo Pesapane, Luciano Mariano, Francesca Magnoni, Anna Rotili, Davide Pupo, Luca Nicosia, Anna Carla Bozzini, Silvia Penco, Antuono Latronico, Maria Pizzamiglio,et al.
MDPI AG
Background and Objectives: Breast cancer (BC) is a leading cause of morbidity and mortality worldwide, and accurate assessment of axillary lymph nodes (ALNs) is crucial for patient management and outcomes. We aim to summarize the current state of ALN assessment techniques in BC and provide insights into future directions. Materials and Methods: This review discusses various imaging techniques used for ALN evaluation, including ultrasound, computed tomography, magnetic resonance imaging, and positron emission tomography. It highlights advancements in these techniques and their potential to improve diagnostic accuracy. The review also examines landmark clinical trials that have influenced axillary management, such as the Z0011 trial and the IBCSG 23-01 trial. The role of artificial intelligence (AI), specifically deep learning algorithms, in improving ALN assessment is examined. Results: The review outlines the key findings of these trials, which demonstrated the feasibility of avoiding axillary lymph node dissection (ALND) in certain patient populations with low sentinel lymph node (SLN) burden. It also discusses ongoing trials, including the SOUND trial, which investigates the use of axillary ultrasound to identify patients who can safely avoid sentinel lymph node biopsy (SLNB). Furthermore, the potential of emerging techniques and the integration of AI in enhancing ALN assessment accuracy are presented. Conclusions: The review concludes that advancements in ALN assessment techniques have the potential to improve patient outcomes by reducing surgical complications while maintaining accurate disease staging. However, challenges such as standardization of imaging protocols and interpretation criteria need to be addressed. Future research should focus on large-scale clinical trials to validate emerging techniques and establish their efficacy and cost-effectiveness. Over-all, this review provides valuable insights into the current status and future directions of ALN assessment in BC, highlighting opportunities for improving patient care.
Giovanni Corso, Carmen Criscitiello, Luca Nicosia, Filippo Pesapane, Elisa Vicini, Francesca Magnoni, Andrea Sibilio, Cristina Zanzottera, Alessandra Margherita De Scalzi, Sara Mannucci,et al.
Ovid Technologies (Wolters Kluwer Health)
Metaplastic breast cancer (MpBC) is a rare and aggressive histologic subtype of breast cancer (BC) characterized by the presence of at least two cellular types, commonly epithelial and mesenchymal components. Despite growing evidence that MpBC is a unique entity, it has long been treated as a variant of nonspecial type (NST) BC. MpBC typically shows the phenotype of triple-negative breast cancer (TNBC), but compared to NST-TNBC, it is a relatively chemorefractory tumor associated with worse outcomes. Therefore, there is an urgent need to develop management guidelines specifically for MpBC to improve the prognosis of patients with early MpBC. This expert consensus aims to guide diagnosis and standardize clinical management of early MpBC among treating physicians. We provide guidance on the challenging radiological and pathological diagnosis of MpBC. Evidence on the involvement of genetic predisposition in the development of MpBC is also explored. We emphasize the importance of a multidisciplinary approach for the treatment of patients with early MpBC. The optimal surgery and radiotherapy approach is presented, as well as the opportunity offered by novel therapeutic approaches to increase treatment response in this chemoresistant subtype. Appropriate management of patients with MpBC is critical to reduce the high risk of local and distant recurrence that characterizes this disease.
Laura Gilardi, Lighea Simona Airò Farulla, Giuseppe Curigliano, Giovanni Corso, Maria Cristina Leonardi, and Francesco Ceci
MDPI AG
Invasive lobular cancer (ILC) is the second most frequent histological type of breast cancer (BC) and includes a heterogeneous spectrum of diseases with unique characteristics, especially the infiltrative growth pattern and metastatic spread. [18F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (FDG-PET/CT) is extensively used in oncology and BC patient evaluation. Its role in ILCs is considered suboptimal due to its low FDG avidity. Therefore, ILCs could benefit from molecular imaging with non-FDG tracers that target other specific pathways, contributing to precision medicine. This narrative review aims to summarize the current literature on the use of FDG-PET/CT in ILC and to discuss future opportunities given by the development of innovative non-FDG radiotracers.
Mariarosaria Calvello, Monica Marabelli, Sara Gandini, Elena Marino, Loris Bernard, Matteo Dal Molin, Giulia Di Cola, Cristina Zanzottera, Giovanni Corso, Nicola Fazio,et al.
MDPI AG
Gastric cancer (GC) has long been a ‘Cinderella’ among hereditary cancers. Until recently, single-gene testing (SGT) was the only approach to identify high-risk individuals. With the spread of multigene panel testing (MGPT), a debate arose on the involvement of other genes, particularly those pertaining to homologous recombination (HR) repair. We report our mono-institutional experience in genetic counseling and SGT for 54 GC patients, with the detection of nine pathogenic variants (PVs) (9/54:16.7%). Seven out of fifty (14%) patients who underwent SGT for unknown mutations were carriers of a PV in CDH1 (n = 3), BRCA2 (n = 2), BRCA1 (n = 1), and MSH2 (n = 1), while one patient (2%) carried two variants of unknown significance (VUSs). CDH1 and MSH2 emerged as genes involved in early-onset diffuse and later-onset intestinal GCs, respectively. We additionally conducted MGPT on 37 patients, identifying five PVs (13.5%), including three (3/5:60%) in an HR gene (BRCA2, ATM, RAD51D) and at least one VUS in 13 patients (35.1%). Comparing PV carriers and non-carriers, we observed a statistically significant difference in PVs between patients with and without family history of GC (p-value: 0.045) or Lynch-related tumors (p-value: 0.036). Genetic counseling remains central to GC risk assessment. MGPT appeared advantageous in patients with unspecific phenotypes, although it led to challenging results.
Luca Nicosia, Anna Carla Bozzini, Filippo Pesapane, Anna Rotili, Irene Marinucci, Giulia Signorelli, Samuele Frassoni, Vincenzo Bagnardi, Daniela Origgi, Paolo De Marco,et al.
MDPI AG
This study aims to evaluate the Average Glandular Dose (AGD) and diagnostic performance of CEM versus Digital Mammography (DM) as well as versus DM plus one-view Digital Breast Tomosynthesis (DBT), which were performed in the same patients at short intervals of time. A preventive screening examination in high-risk asymptomatic patients between 2020 and 2022 was performed with two-view Digital Mammography (DM) projections (Cranio Caudal and Medio Lateral) plus one Digital Breast Tomosynthesis (DBT) projection (mediolateral oblique, MLO) in a single session examination. For all patients in whom we found a suspicious lesion by using DM + DBT, we performed (within two weeks) a CEM examination. AGD and compression force were compared between the diagnostic methods. All lesions identified by DM + DBT were biopsied; then, we assessed whether lesions found by DBT were also highlighted by DM alone and/or by CEM. We enrolled 49 patients with 49 lesions in the study. The median AGD was lower for DM alone than for CEM (3.41 mGy vs. 4.24 mGy, p = 0.015). The AGD for CEM was significantly lower than for the DM plus one single projection DBT protocol (4.24 mGy vs. 5.55 mGy, p < 0.001). We did not find a statistically significant difference in the median compression force between the CEM and DM + DBT. DM + DBT allows the identification of one more invasive neoplasm one in situ lesion and two high-risk lesions, compared to DM alone. The CEM, compared to DM + DBT, failed to identify only one of the high-risk lesions. According to these results, CEM could be used in the screening of asymptomatic high-risk patients.
Francesca Magnoni, Beatrice Bianchi, Giovanni Corso, Erica Anna Alloggio, Susanna Di Silvestre, Giuliarianna Abruzzese, Virgilio Sacchini, Viviana Galimberti, and Paolo Veronesi
MDPI AG
Advances in treatments, screening, and awareness have led to continually decreasing breast cancer-related mortality rates in the past decades. This achievement is coupled with early breast cancer diagnosis. Ductal carcinoma in situ (DCIS) and microinvasive breast cancer have increasingly been diagnosed in the context of mammographic screening. Clinical management of DCIS is heterogenous, and the clinical significance of microinvasion in DCIS remains elusive, although microinvasive DCIS (DCIS-Mi) is distinct from “pure” DCIS. Upfront surgery has a fundamental role in the overall treatment of these breast diseases. The growing number of screen-detected DCIS diagnoses with clinicopathological features of low risk for local recurrence (LR) allows more conservative surgical options, followed by personalised adjuvant radiotherapy plans. Furthermore, studies are underway to evaluate the validity of surgery omission in selected low-risk categories. Nevertheless, the management, the priority of axillary surgical staging, and the prognosis of DCIS-Mi remain the subject of debate, demonstrating how the paucity of data still necessitates adequate studies to provide conclusive guidelines. The current scientific scenario for DCIS and DCIS-Mi surgical approach consists of highly controversial and diversified sources, which this narrative review will delineate and clarify.
Giovanni Corso, Sara Gandini, Oriana D’Ecclesiis, Manuelita Mazza, Francesca Magnoni, Paolo Veronesi, Viviana Galimberti, and Carlo La Vecchia
Ovid Technologies (Wolters Kluwer Health)
Background and aims The risk of developing breast cancer in transgender individuals [male-to-female (MtF) or female-to-male (FtM)] is still inadequately quantified. We aimed to evaluate the impact of breast cancer in this population. Methods We conducted a systematic literature search and review using the Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines through the PUBMED and SCOPUS databases. We identified six cohort studies (for both populations) plus 35 case reports. Incidence and breast cancer risk quantification were the main outcomes considered. Results FtM individuals had a higher risk of developing breast cancer in comparison to cisgender men [standardized incidence ratio (SIR) = 63.4; 95% confidence interval (CI), 32.2–124.9] but a lower risk than cisgender women (SIR = 0.42; 95% CI, 0.07–2.41). Similarly, MtF individuals were at higher risk of developing breast cancer in comparison to cisgender men (SIR = 22.5; 95% CI, 5.54–91.8) and at lower risk than cisgender women (SIR = 0.30; 95% CI, 0.22–0.42). Conclusion In this systematic study and meta-analysis, we identified that FtM and MtF individuals are at substantially higher risk of developing breast cancer in comparison to cisgender men, though at lower risk than cisgender women. These individuals, in the absence of defined guidelines for breast cancer prevention, should periodically undergo breast or chest examinations.
Giovanni Corso, Jaak Ph. Janssens, and Carlo La Vecchia
Ovid Technologies (Wolters Kluwer Health)
Epidemiological studies demonstrate the key role of cancer prevention in reducing global cancer mortality. However, within Europe there are persisting important disparities in incidence and cancer-related mortality. The future strategy of cancer prevention will aim at reducing these disparities through abolition of tobacco educational campaigns to a correct diet and lifestyle through primary prevention, increasing screening (secondary prevention). We also consider focusing on genetics and precision oncology to identify high-risk individuals, and on tertiary prevention to reduce second cancer risk. The application of these approaches could reduce cancer mortality by 35% and increase cancer survival to 70% in 2070. Tobacco control and abolition remain key measures across Europe.
Antonio Toesca, Hyung Seok Park, Jai Min Ryu, Yeon Jin Kim, Jeea Lee, Claudia Sangalli, Patrick Maisonneuve, Emilia Marrazzo, Giada Pozzi, Guglielmo Gazzetta,et al.
Oxford University Press (OUP)
Giovanni Corso, Valentina Tagliaferri, Giulia Massari, Antonio Cioffi, Elisabetta Maria Cristina Rossi, Paolo Veronesi, and Francesca Magnoni
Springer Science and Business Media LLC
Francesca Magnoni, Giovanni Corso, Patrick Maisonneuve, Giulia Massari, Luca Alberti, Giulia Castelnovo, Maria Cristina Leonardi, Virgilio Sacchini, Viviana Galimberti, and Paolo Veronesi
Springer Science and Business Media LLC
Viviana Galimberti, Sabrina Kahler Ribeiro Fontana, Elisa Vicini, Consuelo Morigi, Manuela Sargenti, Giovanni Corso, Francesca Magnoni, Mattia Intra, and Paolo Veronesi
Elsevier BV
Meric A. Altinoz, Francesca Magnoni, Aysel Ozpinar, and Giovanni Corso
Springer International Publishing
Francesco Ferrara, Giulia Massari, Valentina Tagliaferri, and Giovanni Corso
Springer International Publishing
Giulia Massari, Valentina Tagliaferri, and Giovanni Corso
Springer International Publishing